A Phase 3 interventional study of MMH-407 and Placebo in Viral Respiratory Infection, sponsored by Materia Medica Holding. Completed at 26 sites in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-05-17.
Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the efficacy and safety of ММН-407 in treatment of acute respiratory viral infection (ARVI).
Design: multicenter, double blind, placebo-controlled, parallel group randomized clinical trial.
The study will enroll outpatients of either gender aged 18-70 years old with clinical manifestations of ARVI within the first day after the onset of the disease during seasonal ARVI morbidity.
After signing patient information sheet and informed consent form, medical history, thermometry, objective examination, laboratory tests and concomitant medication will be performed. Severity of ARVI symptoms is evaluated with 4-point scale.
The nasopharyngeal swabs for PCR diagnosis and verification of respiratory viruses will be performed prior to therapy to confirm the viral etiology of ARVI.
If a patient meets all inclusion criteria and does not have any exclusion criteria, at Visit 1 (Day 1) he/she will be randomized into one of two groups: the 1st group will take MMH-407 according to the dosage regimen for 5 days; the 2nd group will take Placebo according to MMH-407 dosage regimen for 5 days.
The study will use electronic patient diary for recording morning and evening axillary body temperature (measured using a mercury-free Geratherm Classic thermometer) and disease symptoms (Symptom Severity Score). Besides, antipyretic dosing (if applicable) and any aggravation in a patient's condition (if applicable, for safety evaluation/AE documentation) will also be recorded in a patient diary. The investigator will provide instructions on filling the diary; at Visit 1 the patient together with a doctor will record ARVI symptom severity and body temperature in the diary.
Patient will be observed for 14 days (screening, randomization - Day 1, treatment period - 5 days, follow-up - up to 2 days; deferred "phone visit" - Day 14).
During the treatment and follow-up period the patients or investigators will make 3 visits and the fourth "phone visit" will be scheduled additionally: 1) visits by physician/patient - on Days 1, 5 and 7 (Visits 1, 2 and 3) - in a study center or at home; 2) "phone visit" (Visit 4) - on Day 14.
At Visits 2 and 3, the investigator will perform an objective examination, document changes in the symptoms and concomitant medications to check patient diaries. At Visit 3 compliance will be evaluated and laboratory tests will be performed. "Phone visit" is carried out to interview the patient about his/her condition, presence/absence of secondary bacterial/viral complications and use of antibiotics.
During the study, symptomatic therapy and therapy for their co-morbidities are allowed with the exception of the drugs indicated in the section "Prohibited Concomitant Treatment".
Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tablet for oral use. One tablet per intake. On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily. The drug is administered not during meals (i.e. between the meals or 15-30 minutes before meal). The tablet should be held in mouth until complete dissolution.
Drug: MMH-407
According to the scheme of receiving MMN-407 until the end of the study.
Drug: Placebo
Oral use.
Also known as: Raphamin
Oral use.
Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms
Outcome Measure is evaluated on the basis of the "ARVI severity scale" to calculate total symptom score (TSS) in patients with confirmed virus by Polymerase chain reaction (PCR). ARVI's resolution criteria: temperature ≤37.3°С + TSS ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".
Time frame: 14 days of observation.
Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed)
Outcome Measure is based on the area under the curve (AUC) for TSS. AUC was calculated between 6 points (by TSS for every 6 days of the treatment and observation). The minimum value for the AUC was "0" and the maximum value was "234" units (day\*score). Higher TSS and AUC scores meant worse results.
Time frame: On days 1- 6 of the observation.
Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed)
ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".
Time frame: On days 3, 4, 5 and 6 of observation.
Time to Resolution of Acute Respiratory Viral Infection Symptoms (Clinically Diagnosed and/or PCR-confirmed)
Acute Respiratory Viral Infection (ARVI) Symptoms resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".
Time frame: 14 days of observation.
Percentage of Patients With Resolution of Acute Respiratory Viral Infection (PCR-confirmed)
Outcome Measure is based on the Percentage of Patients With Resolution of Acute Respiratory Viral Infection, confirmed by Polymerase chain reaction (PCR), i.e virus detection. Acute Respiratory Viral Infection resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".
Time frame: On days 3, 4, 5 and 6 of observation.
Dosing Frequency of Antipyretics.
Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy.
Time frame: On days 1, 2, 3 of therapy.
Percentage of Patients Reporting Worsening of Illness
Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.
Time frame: From day 4 to day 14 of the observation period.
Occurrence and Characteristics of Adverse Events (AEs)
Severity of AEs, its causal relationship to the study drug, and outcomes.
Time frame: From day 1 to day 7 of the treatment period.
Changes in Vital Signs: Blood Pressure.
Outcome Measure is based on the medical records. Blood Pressure was measured by the physician in every visit (on days 1, 5, and 7).
Time frame: On days 1, 5 and 7 of the treatment period.
Changes in Vital Signs: Pulse Rate (Heart Rate).
Outcome Measure is based on the medical records. Pulse Rate (Heart Rate) was measured by the physician in every visit (on days 1, 5, and 7).
Time frame: On days 1, 5 and 7 of the treatment period.
Changes in Vital Signs: Respiration Rate (Breathing Rate).
Outcome Measure is based on the medical records. Respiration Rate (Breathing Rate) was measured by the physician in every visit (on days 1, 5, and 7).
Time frame: On days 1, 5 and 7 of the treatment period.
Percentage of Patients With Clinically Relevant Laboratory Abnormalities
Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which were beyond the reference values at the end of treatment.
Time frame: From day 1 to day 7 of the treatment period.
| Milestone | MMH-407 | Placebo |
|---|---|---|
| Started | 118 | 122 |
| Completed | 118 | 122 |
| Not completed | 0 | 0 |
Outcome Measure is evaluated on the basis of the "ARVI severity scale" to calculate total symptom score (TSS) in patients with confirmed virus by Polymerase chain reaction (PCR). ARVI's resolution criteria: temperature ≤37.3°С + TSS ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness), and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".
| days | MMH-407 | Placebo |
|---|---|---|
| Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms | 4.1 ± 1.9 | 5.0 ± 2.5 |
Outcome Measure is based on the area under the curve (AUC) for TSS. AUC was calculated between 6 points (by TSS for every 6 days of the treatment and observation). The minimum value for the AUC was "0" and the maximum value was "234" units (day\*score). Higher TSS and AUC scores meant worse results.
| day*score | MMH-407 | Placebo |
|---|---|---|
| Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed) | 48.5 ± 21.7 | 52.6 ± 24.0 |
ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".
| Participants | MMH-407 | Placebo |
|---|---|---|
| Day 3 | 15 | 8 |
| Day 4 | 44 | 38 |
| Day 5 | 74 | 70 |
| Day 6 | 86 | 85 |
Acute Respiratory Viral Infection (ARVI) Symptoms resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".
| days | MMH-407 | Placebo |
|---|---|---|
| Time to Resolution of Acute Respiratory Viral Infection Symptoms (Clinically Diagnosed and/or PCR-confirmed) | 4.4 ± 2.2 | 4.8 ± 2.4 |
Outcome Measure is based on the Percentage of Patients With Resolution of Acute Respiratory Viral Infection, confirmed by Polymerase chain reaction (PCR), i.e virus detection. Acute Respiratory Viral Infection resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 6 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. The range of TSS was from "0" to "39".
| Participants | MMH-407 | Placebo |
|---|---|---|
| Day 3 | 12 | 3 |
| Day 4 | 28 | 22 |
| Day 5 | 54 | 38 |
| Day 6 | 60 | 48 |
Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy.
| number of doses | MMH-407 | Placebo |
|---|---|---|
| Day 1 | 0.30 ± 0.68 | 0.38 ± 0.67 |
| Day 2 | 0.19 ± 0.48 | 0.24 ± 0.53 |
| Day 3 | 0.03 ± 0.22 | 0.04 ± 0.20 |
Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.
| Participants | MMH-407 | Placebo |
|---|---|---|
| Percentage of Patients Reporting Worsening of Illness | 1 | 3 |
Severity of AEs, its causal relationship to the study drug, and outcomes.
| Number of events | MMH-407 | Placebo |
|---|---|---|
| Number of AE | 9 | 11 |
| Mild severity | 9 | 11 |
| No relationship with the study drug | 8 | 11 |
| Probable relationship to study drug | 1 | 0 |
Outcome Measure is based on the medical records. Blood Pressure was measured by the physician in every visit (on days 1, 5, and 7).
| mmHg | MMH-407 | Placebo |
|---|---|---|
| Systolic blood pressure/Visit 1 | 121.0 ± 10.0 | 121.0 ± 10.1 |
| Systolic blood pressure/Visit 2 | 120.0 ± 8.5 | 120.0 ± 8.4 |
| Systolic blood pressure/Visit 3 | 120.0 ± 8.2 | 119.0 ± 9.4 |
| Diastolic blood pressure/Visit 1 | 75.0 ± 7.5 | 75.1 ± 7.3 |
| Diastolic blood pressure/Visit 2 | 74.9 ± 6.3 | 74.8 ± 6.4 |
| Diastolic blood pressure/Visit 3 | 74.6 ± 6.6 | 74.8 ± 7.2 |
Outcome Measure is based on the medical records. Pulse Rate (Heart Rate) was measured by the physician in every visit (on days 1, 5, and 7).
| bpm | MMH-407 | Placebo |
|---|---|---|
| Heart rate/Visit 1 | 86.9 ± 12.9 | 88.0 ± 13.0 |
| Heart rate/Visit 2 | 73.5 ± 7.4 | 74.4 ± 9.0 |
| Heart rate/Visit 3 | 71.1 ± 5.8 | 71.7 ± 7.1 |
Outcome Measure is based on the medical records. Respiration Rate (Breathing Rate) was measured by the physician in every visit (on days 1, 5, and 7).
| breaths/min | MMH-407 | Placebo |
|---|---|---|
| Breathing rate/Visit 1 | 17.4 ± 1.6 | 17.5 ± 1.6 |
| Breathing rate/Visit 2 | 16.6 ± 1.4 | 16.7 ± 1.4 |
| Breathing rate/Visit 3 | 16.4 ± 1.3 | 16.4 ± 1.3 |
Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which were beyond the reference values at the end of treatment.
| Participants | MMH-407 | Placebo |
|---|---|---|
| Percentage of Patients With Clinically Relevant Laboratory Abnormalities | 0 | 1 |
Collected over During 6 days (start after taking the first dose of the study drug, during the entire period of the study therapy - 5 days and within 24 hours after the last dose of the study drug).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MMH-407 | 0/118 (0%) | 0/118 (0%) | 9/118 (7.6%) |
| Placebo | 0/122 (0%) | 1/122 (0.8%) | 9/118 (7.6%) |
| Event | MMH-407 | Placebo |
|---|---|---|
| Community-acquired pneumoniaInfections and infestations | 0/118 | 1/122 |
| Event | MMH-407 | Placebo |
|---|---|---|
| Epigastric painGastrointestinal disorders | 2/118 | 0/118 |
| DiarrheaGastrointestinal disorders | 0/118 | 1/118 |
| Dry mouthGastrointestinal disorders | 1/118 | 0/118 |
| NauseaGastrointestinal disorders | 0/118 | 1/118 |
| SinusitisInfections and infestations | 0/118 | 1/118 |
| Purulent bronchitisInfections and infestations | 1/118 | 1/118 |
| Acute nasopharyngitisInfections and infestations | 1/118 | 0/118 |
| Acute tubootitisInfections and infestations | 1/118 | 0/118 |
| Herpes simplexInfections and infestations | 1/118 | 1/118 |
| Increase in the percentage of basophilsInvestigations | 0/118 | 1/118 |
| Age, Continuous(years) | MMH-407 | Placebo | Total |
|---|---|---|---|
| Mean | 38.5 ± 12.6 | 38.5 ± 11.6 | 38.5 ± 12.1 |
| Sex: Female, Male(Participants) | MMH-407 | Placebo | Total |
|---|---|---|---|
| Female | 79 | 68 | 147 |
| Male | 39 | 54 | 93 |
| Race and Ethnicity Not Collected(Participants) | MMH-407 | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | MMH-407 | Placebo | Total |
|---|---|---|---|
| Russia | 118 | 122 | 240 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2019 to primary completion in Apr 2020, 6 months.
Results were first posted in Oct 2021, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MMH-407